The order carried out as a part of the project titled:
IPF: DEVELOPMENT OF A FIRST-IN-CLASS SMALL MOLECULE DRUG CANDIDATE FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS THROUGH CHITOTRIOSIDASE INHIBITION (POIR.01.01.01-00-0551/15)
co-financed by European Union Funds and because of the competitiveness principle. We hereby look for Contractor ready to perform the service:
Professional consulting and advice on pharmacology in the context of study design and verification of research strategy of the company at every stage of drug development up to early phase clinical trials in therapeutic areas of lung diseases (including idiopathic pulmonary fibrosis-IPF) and metabolic diseases (including nonalcoholic steatohepatitis-NASH).